Novo and Lilly cut prices of weight-loss drugs in China

Novo Nordisk and Eli Lilly are reducing prices for their obesity drugs, Wegovy and Mounjaro, in China. Novo confirmed a price adjustment for Wegovy, with reports indicating a 48% cut in some provinces. Lilly's Mounjaro prices will also decrease starting January 1. The move aims to alleviate treatment costs for patients as obesity rates rise in China. Both companies face competition from local drugmakers and rivals, especially with Novo's Wegovy patent expiring in 2026. Novo previously cut prices in India and the U.S. as part of a strategy to attract cash-paying consumers.